Abstract:Background Hepatocellular carcinoma (HCC) is one of the most lethal human tumors with extensive intratumor heterogeneity (ITH). Serine protease 3 (PRSS3) is an indispensable member of the trypsin family and has been implicated in the pathogenesis of several malignancies, including HCC. However, the paradoxical effects of PRSS3 on carcinogenesis due to an unclear molecular basis impede the utilization of its biomarker potential. We hereby explored the contribution of PRSS3 transcripts to tumor functional heterogeneity by systematically dissecting the expression of four known splice variants of PRSS3 ( PRSS3-SVs, V1~V4 ) and their functional relevance to HCC. Methods The expression and DNA methylation of PRSS3 transcripts and their associated clinical relevance in HCC were analyzed using several publicly available datasets and validated using qPCR-based assays. Functional experiments were performed in gain- and loss-of-function cell models, in which PRSS3 transcript constructs were separately transfected after deleting PRSS3 expression by CRISPR/Cas9 editing. Results PRSS3 was aberrantly differentially expressed toward bipolarity from very low ( PRSS3 Low ) to very high ( PRSS3 High ) expression across HCC cell lines and tissues. This was attributable to the disruption of PRSS3-SVs , in which PRSS3-V2 and/or PRSS3-V1 were dominant transcripts leading to PRSS3 expression, whereas PRSS3-V3 and -V4 were rarely or minimally expressed. The expression of PRSS3-V2 or -V1 was inversely associated with site-specific CpG methylation at the PRSS3 promoter region that distinguished HCC cells and tissues phenotypically between hypermethylated low-expression (m PRSS3-SV Low ) and hypomethylated high-expression (um PRSS3-SV High ) groups. PRSS3-SVs displayed distinct functions from oncogenic PRSS3-V2 to tumor-suppressive PRSS3-V1 , -V3 or PRSS3-V4 in HCC cells. Clinically, aberrant expression of PRSS3-SVs was translated into divergent relevance in patients with HCC, in which significant epigenetic downregulation of PRSS3-V2 was seen in early HCC and was associated with favorable patient outcome. Conclusions These results provide the first evidence for the transcriptional and functional characterization of PRSS3 transcripts in HCC. Aberrant expression of divergent PRSS3-SVs disrupted by site-specific CpG methylation may integrate the effects of oncogenic PRSS3-V2 and tumor-suppressive PRSS3-V1 , resulting in the molecular diversity and functional plasticity of PRSS3 in HCC. Dysregulated expression of PRSS3-V2 by site-specific CpG methylation may have potential diagnostic value for patients with early HCC.

An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression

MiR-155 and Its Functional Variant Rs767649 Contribute to the Susceptibility and Survival of Hepatocellular Carcinoma

Identification of Potential Functional Variants and Genes at 18q21.1 Associated with the Carcinogenesis of Colorectal Cancer.

The Inherited Variations of a P53-Responsive Enhancer in 13q12.12 Confer Lung Cancer Risk by Attenuating TNFRSF19 Expression

Functional Short Tandem Repeat Polymorphism of PTPN11 and Susceptibility to Hepatocellular Carcinoma in Chinese Populations.

Association Between a Variant in MicroRNA-646 and the Susceptibility to Hepatocellular Carcinoma in a Large-Scale Population

Genome-wide functional integration identified MAZ-controlled RPS14 dysregulation in hepatocellular carcinoma

Nine Susceptibility Loci for Hepatitis B Virus-Related Hepatocellular Carcinoma Identified by A Pilot Two-Stage, Genome-Wide Association Study

A 16q22.1 Variant Confers Susceptibility to Colorectal Cancer As a Distal Regulator of ZFP90

Systematical analyses of variants in DNase I hypersensitive sites to identify hepatocellular carcinoma susceptibility loci in a Chinese population

Heritable Variants in the Chromosome 1q22 Locus Increase Gastric Cancer Risk Via Altered Chromatin Looping and Increased UBAP2L Expression

rs401681 and rs402710 confer lung cancer susceptibility by regulating TERT expression instead of CLPTM1L in East Asian populations

Genome-wide enhancer-gene regulatory maps link causal variants to target genes underlying human cancer risk

CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma

Locus 5p13.1 may be associated with the selection of cancer-related HBV core promoter mutations

Identification of rs2736099 as a novel cis-regulatory variation for TERT and implications for tumorigenesis and cell proliferation

A genetic variant in the promoter region of miR-877 is associated with an increased risk of hepatocellular carcinoma

PRMT9 Promotes Hepatocellular Carcinoma Invasion and Metastasis Via Activating PI3K/Akt/GSK-3/Snail Signaling

Genetic Variants in p53 Pathway Genes Affect Survival of Patients with HBV-Related Hepatocellular Carcinoma

Genetic polymorphisms in DNA double-strand break repair genes XRCC5, XRCC6 and susceptibility to hepatocellular carcinoma.

TRMT10C gene polymorphisms confer hepatoblastoma susceptibility: evidence from a seven-center case-control study